We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microfluidic Device Automatically Monitors Whole Blood Hemostasis

By LabMedica International staff writers
Posted on 20 Jan 2016
An assay has been devised for testing blood's clotting tendency, also known as hemostasis, which could one day prove lifesaving in a variety of clinical situations in which a patient's health is jeopardized by abnormal blood coagulation and platelet function.

The microfluidic based device assay can be used with blood samples or potentially be integrated into patients' blood flow lines; so that one day clinicians could have the foresight they need to prevent life-threatening events such as blood clotting or internal hemorrhaging.

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University (Boston, MA, USA) devised a microfluidic device that mimics a network of stenosed arteriolar vessels, permitting evaluation of blood clotting within small sample volumes under pathophysiological flow. More...
By applying a clotting time analysis based on a phenomenological mathematical model of thrombus formation, coagulation and platelet function can be accurately measured in vitro in patient blood samples.

The devices were designed to fit on a standard (75 × 50 mm) microscope slide to simplify microscopic analysis using appropriate software and they used SU8 2075 master templates (MicroChem Corporation; Newton, MA, USA) fabricated on Si (100) wafers using photolithography. The devices were fabricated using soft lithography of polydimethylsiloxane (PDMS). The device contains hollow channels that mimic the pathology of the narrowing of small blood vessels, which occurs in patients as a side effect of medical conditions or treatments and can often cause a shift in the fluid mechanics of blood flow that can lead to life-threatening blood clots or internal bleeds.

In a large animal study already conducted, the team perfused blood directly from a living vessel into a microfluidic device to measure clinical clotting parameters over time, and they recorded precise predictions for clotting times for blood samples that were far more accurate and faster than currently-used clinical assays. The real-time monitoring ability of the device could also assess patients' coagulation status almost continuously, in stark contrast to today's standard of once or twice a day testing procedures, thereby reducing the likelihood of toxic side effects resulting from anticoagulation therapies. The team also demonstrated that the device can detect abnormal platelet function in patients with a rare bleeding disorder that cannot be easily identified using conventional assays.

Abhishek Jain, PhD, a postdoctoral fellow and lead author of the study, said, “The physics of what's happening inside our bodies is a major contributor to the reasons why blood clots form or why clotting fails during surgeries, traumas, or extracorporeal medical procedures. By mimicking the physics of blood clotting in our device more precisely, we hope this technology can one day be used to save lives.” The study was published on January 6, 2016, in the journal Nature Communications.

Related Links:

Wyss Institute for Biologically Inspired Engineering 
MicroChem Corporation 



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Urine Analyzer
respons® UDS100
New
Clinical Chemistry Kit
For Biossays analyzers
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.